Личный помощник руководителя( х10 )

Описание

Anna Chistyakova Date of Birth 21 of August, 1973 Address Russia, Moscow, Dmitry Ulianov’ str, 4 Contacts +7 916 372 55 12 annachistyakova17@gmail.com Career objectives Country Head, BU Head, BD manager Education background 1997 - 1999 1990 - 1995St. Petersburg’s Pedagogical University Faculty of Pedagogy & Psychology, specialization – clinical psychology & psychological assistance. St. Petersburg’s University of Culture & Arts, specialization – technical translator

Languages knowledge Russian – native, English – advanced, Arabic (Saudi dialect) - basic Trainings & Courses Career portfolio August 2022 – May, 2024 Sopharma, mid-sized Bulgarian company, www.sopharmagroup.com Regional Head (Russia, Belarus & Central Asia) •Responsible for Region business for 100 Mio Euro (No 1 in Net Revenue & EBITDA in Sopharma) •In direct reporting – 12 FTE, Total Region - 64 FTE Responsible for: in Russia - business development from scratch: until 2022, for 20 years, the company's business was assigned to a Sopharma partner •Developing and implementing business strategies to increase the company’s market share and profitability in the Region 1980 -1990St. Petersburg’s gymnasium No 397 named by G. Starovoytova Advanced English language study 2023 – Leadership Academy by Vladimir Borachev (Bilgaria, Sofia) 2017 – 2019 STADA Leadership Program offered in collaboration with Ashridge Executive Education, England 2013 The basics of building a team by using a Myers Briggs personal types indicator, Pentagrams Group 2011 Promotion strategy for pharmaceutical products and brands Comcon Pharma, Upgraded Course Marketing background (educational program lead by Spanish Trade Chamber for Spanish companies, located at RU, employees, Universitat de Barcelona, 2001- 2003

•Managing all operations within the country which includes taking responsibility for profit, revenue, cash and quality targets •Establishing productive and professional relationships with Distributors & Pharmacy Chains, as well as State organizations •Coordinating with the global management team to ensure the consistency of company strategy •Understanding the country’s legal and business environment to ensure the company operates within legal boundaries •Identifying business opportunities, potential partners, markets, and competition •Recruiting, training, and managing staff to deliver top customer service •Monitoring the performance of the branch and reporting to the senior management •Managing budgets and financial plans as well as controlling expenditure •Manage crisis and resolve any escalating issues that may arise August 2021 – August 2022 IPSEN, mid-sized global biopharmaceutical company, www.ipsen.com Business Excellence Head, CHC division, Russia & CIS/ direct reporting to GM •Responsible for OTC portfolio (Smecta, Tanakan, Forlax, Fortrance, Ezyclen) •In direct reporting – 2 SFE manager, 2 Market analytic, Event Manager, Digital Manager, IT manager Responsible for: •Creating all BEX tools from scratch (dashboards, BI reporting system, KPI trackers) •SF effectiveness management in Ru & CIS •Business development projects (Search and management of new potential projects with focus on local initiatives, member of Global NPD board) •Portfolio management (optimization, prioritization, launches, pipeline & wish list portfo-lio) •Digital & Omnichannel approach for HCP Major achievements as BEX head: •SFE re-structuring (CHC/ Rx and Mix categories approach based on coverage & target-ing) & development of a system for controlling sales force performance in terms of prod-ucts and regions of presence (project started from 1Q 2021) •Pharma Chains categorization & investment calculator (in cooperation with Commercial Dep, project started from 4Q 2021 during contracting annual campaign) •Development of an extension of the Smecta line with biotics produced by Kraft, Saint Pet)

February 2021 - August 2021 Nanocosmetech INC International Marketing Head / direct reporting to CEO (responsible for 49 countries, incl Russia & CIS), HY contract •Japanese professional cosmetic, was found at 2002 Main tasks: •To build a strategic vision of professional & retail portfolio • Portfolio prioritization & efforts allocation •To create marketing oriented approach ( incl strong experienced staff, official procedures, KPI system, analytic system, etc) December 2019 – September 2020 STADA, multinational pharmaceutical company (Moscow, www.stada .ru) HQ Bad Vilbel, Germany CHC (Consumer Health Care) Business Unit Head, interim / Direct reporting to GM (Country Head, RU & CIS) •Responsible for OTC portfolio (80% of total Stada RU portfolio, incl. ex-Takeda brands – CardioMagnyl, Vitrum, Arta, CaD3 & ex- GSK brands – Coldrex, Tavegyl) •In direct reporting – 4 BU Heads, Trade Marketing Department. Total BU 640 FTE. •I’m a member of STADA Talent Profiling (Commercial Leaders), in Dec 2019 a reloca-tion program to Europe’s office was offered •STADA market performance (IQVIA, May 2020) - 1 st place at OTC segment, value. •Before Takeda portfolio was integrated, STADA had NO 3, value at OTC market (IQVIA, Jan, 2020) Major achievements as CHC BU head 1.Was a stream leader for Takeda’s all brands transfer, Takeda’s employee (sales & market-ing) transfer during Due Diligence process (Dec 2019 – March 2020) 2.SEC member (Senior Executive Committee) 3.Sales Force & Marketing re-organization based on Field Force synergy & portfolio prior-itization (new org structure start from September 2020) 4.Trade Marketing function launch (March 2020) 5.LifeStyle BU head, Interim (ex-Takeda portfolio), Marketing Manager & 2 NSM in direct reporting. Total BU 164 FTE. APRIL 2013 – December 2019 Man’s and Woman’s Health BU Head (uro + gyno portfolio) •23% value share in STADA portfolio, 2019

•Direct reporting to CHC BU Head •Marketing manager, NSM in direct reporting, total 120 FTE Responsible for: •Main business indicators control & implementation ( P&L, MS, sell-out business plan, SIT level, following the company’s values) •Portfolio management (optimization, prioritization, launches, pipeline & wish list portfo-lio) •Short – team (1 year) & mid-term (3 years) marketing strategy planning, approving, fol-lowing & updating •SF effectiveness management (follow the targeting, promo grid, marketing strategy) •Pharmacy Chains management (annual commercial contracts & trade marketing pro-grams planning & quarterly controlling), TOP10 Chains personal regular negotiations (coordinated by KAMs) •Risk management ( quarterly base) •People management – holding annual employee’s evaluation, creating & controlling an annual individual employee’s plan, incentive & promotional programs, new business function launches. Middle level management recruitment. External assessment for mar-keting & SF managers •All business reporting (MBR/YBR, Deep Dives, SteerCo, DD status) for GM, CEO. Major achievements as MWHealth BU head •Jan, 2019 – Integration of Man’s Health and Woman’s Health in one Department , stream leader – the whole range of activities ( structure, KPI, portfolio prioritization, employee’s assessment, etc) •April, 2013 – Man’s health BU as a start up, project leader •2019 – project “ Portfolio prioritization and resources allocation”, participant, in coordi-nation with EY Consulting, Bain and Co •2014, 2017, 2019 - Due Diligence, new brands acquisitions ( Neyrodoze, Androdoze, Nefradoze, Vuka Vuka, Phenazalgin) & portfolio acquisitions ( Takeda, GSK) •Starting from 2015 Stada’ value share shows an aggressive increasing trend at URO market, from 9,2% to 18% (IQVIA, YTD, 2019) •Sell out, value, increased by 120% from 2015 to 2019 •Vitaprost value share increased from 31% (2015) to 35% (2019), sell out from 940 Mio RB (2015) to 1,7 Mio Rb (2019). Vitaprost – the most prescribed brand for prostatitis diagnosis, Top -1 profit brand among all Stada OTC brands, tablet’s launch is a most successful launch, accord-ing to distributor’s and Ph Chain’s opinion in 2015.

Vuka Vuka – 2015, relaunch. Brand’s MS in value increased from 0,9% (2015) to 16% (2019), sell out increased in 6 times, from 48 Mio Rb (2015) to 260 Mio Rb (2019). Vuka is a market leader among food supplements for sexual dysfunction, no 5 among all segment’s players (OTC, Rx, FS). Brand awareness is no 2, after Viagra (Comcone, Prindex, 2018) Re-positioning for GYNO portfolio – mix promo, consumer & doctors. Media launch. Depanthol - 375 Mio Rb, TOP-5 brand in category Vaginal infection (6,5% in value), Femilex is 1,85M € sell-out brand growing 14% vs. 2018, is the biggest ‘acid’ player with ~10% in value (#4) at vaginal microflora market May, 2008 – Feb, 2013 Vertex, pharmaceutical company (Saint Petersburg, www. Vertex, spb.ru) Marketing Director, Direct reporting to GM • OTX portfolio (Cosmetics, Gyno, Cardio, Derma) Leading marketing department, 6 Brand Managers in direct reporting, total 18 FTE (marketing, trade marketing, KAM) Sept, 2007 – May, 2008 Fazer, bakery & confectionary company, Saint Petersburg, HQ – Helsinki National Brand Manager, category – Fresh Bakery (85% turnover), direct reporting to Market -ing Director May, 2001 – July, 2007 Chupa Chups Company, Saint Petersburg. HQ – Barcelona Sr. Brand Manager , direct reporting to Marketing Director August. 1998 – May, 2001 Training Manager, direct reporting to NSM Jan, 1992 – August, 1994 Baltic Star Duty Free shop Supervisor Personal features •Leadership mentality, proactive lifestyle, strong and calm, rational thinking, empower others, innovator, learning •My current mission is - to lead a department in a way which allows to achieve an ex-pected by HQ external and internal results

•What is my “golden rule” in business - All big projects are possible in networking ap-proach. To create a working group, set a clear role and tasks, deadlines, responsibili-ties, to create a transparent project developing, to empower and motivate Hobbies •Oriental studies